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SIGNIFICANCE OF PATHOPHYSIOLOGY
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UNDERLYING PATHOPHYSIOLOGY
This nurse is currently employed at an outpatient ambulatory hemodialysis 
(HD) clinic.   National statistics revealed more than 660,000 Americans being 
treated for end stage renal disease (ESRD) and at the state level, Ohio has 
16,182 individuals which are on routine HD with the primary causes 
attributed to diabetes and hypertension (HTN) (National Kidney Foundation 
[NKF], 2017).  This nurse discovered a small patient population ascertained 
ESRD from an inherited familial disorder, particularly polycystic kidney 
disease (PKD).  PKD is the fourth leading cause kidney failure and 
approximately 600,000 individuals have been diagnosed with PKD in the 
United States (U.S.) (NKF, 2017).  PKD causes multiple fluid cysts to grow in 
the kidneys, depending on the size and amount they can damage the kidney, 
decrease kidney function, and lead to renal failure (NKF, 2017). 
There are three types of PKD: autosomal dominant polycystic kidney disease 
(ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and 
acquired cystic kidney disease (ACKD).  ADPKD, which is the most 
predominant occurring in 300,000 to 600,000 individuals per year (Srivastava 
& Patel, 2014).  ADPKD is the most commonly inherited human renal disease 
with mutations on two genes, PKD1 and PKD2, mutations from PKD1 account 
for 85% of ADPKD cases (Sweeney Jr & Avner, 2014).  The PKD1 gene is 
located on chromosome 16 and the PKD2 gene is located on chromosome 4, 
both genes encode for membrane proteins polycystin-1 and polycystin-2, 
mutations lead to increased levels of cyclic adenosine monophosphate 
causing cystogenesis (Srivastava & Patel, 2014).  Autosomal dominant 
diseases affect males and females equally, 50% of the offspring of affected 
parent will have the disease, and generations are not skipped.  Most patients 
with PKD do not present with clinical manifestations until later in in life due 
to the slow growth of the cysts which contributes to a loss of nephrons and a 
decline in the glomerular filtration rate (GFR) (Srivastava & Patel, 2014).  
SIGNS & SYMPTOMS
o Polycystins are proteins which regulate intracellular calcium signaling and are found in tissues such 
as renal tubular epithelia, hepatic bile ducts, and pancreatic bile ducts (Harris &. Torres, 2014).
o Mutations in PKD1 or PKD2 causes a reduction in intracellular calcium, an increase in cyclic 
adenosine monophosphate (cAMP), activation of protein kinase A, and an increase in sensitivity of 
collecting duct principal cells to the constant tonic effect of vasopressin.
o A decrease in calcium signaling and an increase in cAMP causes impaired tubulogenesis. cell 
proliferation, increased fluid secretion, and interstitial inflammation (Silverman, Desai, & Lerma, 
2015).
o Cyst development occurs from dilatations in intact tubules which are connected 
to nephrons.
o Increased cell proliferation and fluid secretion lead to cyst growth causing 
displacement and loss of the normal renal parenchyma.
o Increased cAMP decreases intracellular calcium signaling increasing the size of 
cysts by increasing fluid secretion.
o Impairs renal function and leads to ESRD (Cronec-Le Gall et al., 2013).
o Renal cysts compress the renal vasculature resulting in intrarenal ischemia 
activating the renin-angiotensin-aldosterone system (RAAS).
o Chronic pain caused by cysts rupturing or enlarged kidney compressing other 
structures (Ong, Devuyst, Knebelmann, & Walz, 2015).
o Acute pain is associated with kidney cyst hemorrhage, infection, or stones.
o Urinary tract infections (UTI) are caused by infected renal cysts.
o Cysts block the renal tubules preventing normal drainage causing crystals to 
form and creating kidney stones. 
o Hematuria is caused by the rupturing of cysts or of the small blood vessels 
around the cysts (Silverman, Desai, & Lerma, 2015).
IMPLICATIONS FOR NURSING CARE
•Take patient history and perform assessment.
•Monitor vital signs, particularly blood pressure.
•Palpate bilaterally for flank masses (Yrad & Humphreys, 2017).
•Monitor renal function and urine elimination, hydration, fluid and electrolyte balance.
•Give ACE inhibitors to control hypertension and opioid analgesics for pain (Mallet, Lee, 
Mai, Lopez-Vargas, & Rangan, 2015).
•Provide fluids and foods based on the patient’s condition, encourage increased fluids if the 
patient has a urinary tract infection, and restrict fluids if the patient has renal failure.
•Obtain specimens for urinalysis and culture and sensitivity as ordered to evaluate for 
hematuria, proteinuria, and infection; obtain specimens for laboratory tests for electrolyte 
levels (Reed-Gitomer, 2017).
•Allow the patient to verbalize his feelings and concerns, especially related to possible 
progression of the disease and renal failure; provide support and guidance.
•Prepare the patient for dialysis or renal replacement therapy if indicated.
•Encourage the parents of a child with the infantile form to obtain genetic counseling.
•Refer the patient and his family to community and social services.
CONCLUSION
Although there is no treatable cure for ADPKD, understanding the mode of inheritance and the 
implications is paramount.  Patients with PKD having a basic understanding how the disease is 
inherited and establishing an accurate family history can appreciate how conditions are passed on 
in a family and passed down through generations.  Managing the progression of the disease and 
the symptoms are incremental to slowing the growth of the cysts which may potentially lead to 
end stage renal disease (ESRD).
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Renal Cysts
•Multiple fluid filled cysts form within the kidneys from focal proliferation of single tubular epithelial cells.
Hypertension (HTN) 
•A risk factor associated with a decline in renal function, development of left ventricular hypertrophy,
and increased morbidity.
•The most common manifestation of ADPKD and occurs in 50-70% of cases (Chebib & Torres, 2016).
Pain
•Pain can be present in back, chest, abdominal, or flank.
•Pain is reported in 60% of the cases of adults with ADPKD (Chebib & Torres, 2016).
Urinary Tract Infections
•More common with women and are caused by gram negative bacteria.
•Occurs in 30-50% of the patients (Chebib & Torres, 2016).
Nephrolithiasis
•Renal stones usually composed of uric acid and/or calcium oxalate. Twice as common in ADKPD. 
•Patients with ADPKD patients have a decrease in urine citrate, a substance which prevents the formation 
•of kidney stones.
Hematuria
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